CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the phase III QWINT development program found. In QWINT-1, there was a similar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback